8-K: Coeptis Therapeutics Secures $4.3 Million in Series A Preferred Offering Led by Board Member

Coeptis Therapeutics has successfully raised $4.3 million through a Series A preferred stock offering, led by a board member, to bolster its cell therapy platform development.

Summary

• Coeptis Therapeutics raised $4.3 million through the sale of 4,300 shares of Series A preferred stock at $1,000 per share.
• The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise.
• Investors received a 6.45% non-voting equity interest in two of Coeptis' subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.
• Each share of Series A preferred stock is convertible into common stock at an initial price of $0.40 per share, subject to adjustments.
• The Series A preferred stock will automatically convert to common stock upon a fundraising transaction of at least $20 million.
• The Series A preferred stock is senior to the company's common stock in terms of dividends and liquidation preferences.
• Holders of the Series A preferred stock have voting rights on an as-converted basis, subject to certain limitations.
• The company granted options to acquire 2,400,000 shares of common stock to CEO David Mehalick, exercisable at the closing price on the date of approval.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful capital raise and the support from a board member, but there are some risks and limitations associated with the preferred stock.

Positives

• The $4.3 million capital raise strengthens the company's balance sheet.
• The financing is led by a board member, indicating strong internal confidence.
• The funds will be used for debt repayment, working capital, and general corporate purposes.
• The conversion price of $0.40 per share is a premium to the market price.
• The investment supports the development of innovative cell therapy platforms.

Negatives

• The Series A preferred stock has conversion limitations based on beneficial ownership and market limits.
• The conversion of preferred stock could dilute existing common shareholders.
• The company is reliant on future fundraising to trigger automatic conversion of the preferred stock.

Risks

• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• There is a risk that the company's products in development may fail clinical trials or not receive regulatory approval.
• The company faces competition and may not be able to grow economically.
• Changes in laws or regulations could adversely affect the company.
• The company is subject to economic, business, and competitive factors.

Future Outlook

The company anticipates several significant near-term milestones and plans to allocate the proceeds towards debt repayment, working capital, and general corporate purposes. They are focused on advancing their cell therapy platforms and long-term growth prospects.

Management Comments

• Dave Mehalick, President and CEO, expressed gratitude for investor support, highlighting their shared vision for the company's future.
• Management believes the financing strengthens the balance sheet and supports innovative cell therapy platforms.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on cell therapy. The capital raise allows Coeptis to continue its research and development efforts in a competitive market.

Comparison to Industry Standards

• The $4.3 million raise is a relatively small amount compared to larger biotech companies, but is significant for a company of Coeptis' size.
• The conversion price of $0.40 per share is a premium to the market price, which is a positive sign for investors.
• The 6.45% equity stake in subsidiaries is a unique structure that may attract investors interested in specific technologies.
• Other companies in the cell therapy space, such as Kite Pharma and Juno Therapeutics, have raised significantly larger amounts of capital, but Coeptis is at an earlier stage of development.

Related Party Transactions

• The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the preferred stock.
• Employees may benefit from the company's improved financial position.
• Customers may benefit from the development of new cell therapy platforms.
• Creditors may benefit from the repayment of outstanding obligations.

Next Steps

• The company will allocate the proceeds towards repayment of outstanding obligations, working capital, and general corporate purposes.
• The company will continue to develop its cell therapy platforms.
• The company may seek additional funding in the future to trigger the automatic conversion of the Series A preferred stock.

Key Dates

Keywords

Series A Preferred Stock, Cell Therapy, Biopharmaceutical, Capital Raise, Convertible Stock, SNAP Biosciences, GEAR Therapeutics, Equity Financing, Nasdaq, COEP